Skip to main content
SpringerLink
Log in

Immunotherapy for Alzheimer’s Disease

  • Chapter
  • First Online:
Neuroimmune Pharmacology

  • 2716 Accesses

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder in which memory and cognitive dysfunctions are the earliest symptoms. Pathologically, the disorder is characterized by neuron loss in hippocampus and multiple cortical regions, along with the formation of extracellular amyloid plaques and intracellular neurofibrillary tangles. The amyloid in this disorder is comprised largely of a peptide called Aß, which is a degradation product of a protein with unknown function referred to as the amyloid precursor protein. The genetics of dominant inherited forms of Alzheimer’s disease implicate increased production of the long form of the Aß peptide as the critical feature leading to unavoidable development of the disease. This recognition has led many to consider anti-amyloid therapeutics as a means of slowing or arresting the disease. One approach that may become the first to test the so-called “amyloid hypothesis” is immunotherapy. Both vaccination and monoclonal antibody therapies have been tested with considerable success in mouse models of amyloid deposition. These approaches can prevent the formation of amyloid deposits, remove already existing deposits, and reverse the memory deficits associated with amyloid deposition in these mice. A human clinical trial was cut short due to an apparent autoimmune reaction in a fraction of the patients, but the results from this truncated trial still suggest that there may be therapeutic benefits of the approach. Current research is focusing on trying to understand the mechanisms by which antibodies directed against Aß aid in clearing the amyloid deposits, how the vaccines might be constructed to overcome self-tolerance without evoking autoimmune reactions, and testing various monoclonal antibody preparations for efficacy in clinical trials. Even partial success in slowing the progression of this disease can have considerable societal and economic impact. Furthermore, verification of the amyloid hypothesis will encourage development of a number of other anti-amyloid therapies that may synergize with the immunotherapeutic approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs DH (2005) Prototype Alzheimer’s disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174(3):1580–1586

    Article  CAS  PubMed  Google Scholar 

  • Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21(3):383–421

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7(3):369–372

    Article  CAS  PubMed  Google Scholar 

  • Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8):916–919. doi:10.1038/78682

    Article  CAS  PubMed  Google Scholar 

  • Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci U S A 100(4):2023–2028

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64(1):94–101. doi:10.1212/01.WNL.0000148604.77591.67

    Article  CAS  PubMed  Google Scholar 

  • Bowers WJ, Mastrangelo MA, Stanley HA, Casey AE, Milo LJ Jr, Federoff HJ (2005) HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol Aging 26(4):393–407. doi:10.1016/j.neurobiolaging.2004.04.006

    Article  CAS  PubMed  Google Scholar 

  • Chauhan NB, Siegel GJ (2002) Reversal of amyloid beta toxicity in Alzheimer’s disease model Tg2576 by intraventricular antiamyloid beta antibody. J Neurosci Res 69(1):10–23. doi:10.1002/jnr.10286

    Article  CAS  PubMed  Google Scholar 

  • Chauhan NB, Siegel GJ (2003) Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res 74(1):142–147. doi:10.1002/jnr.10721

    Article  CAS  PubMed  Google Scholar 

  • Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8(1):79–84. doi:10.1038/nn1372

    Article  CAS  PubMed  Google Scholar 

  • Corbyn Z (2013) New set of Alzheimer’s trials focus on prevention. Lancet 381(9867):614–615

    Article  PubMed  Google Scholar 

  • Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123):921–923

    Article  CAS  PubMed  Google Scholar 

  • Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG (2003) Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15(4):505–514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 98(15):8850–8855. doi:10.1073/pnas.151261398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE (2001) Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer’s disease-associated beta-amyloid 1–42 peptide. DNA Cell Biol 20(11):723–729. doi:10.1089/10445490152717587

    Article  CAS  PubMed  Google Scholar 

  • Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci 5(5):452–457. doi:10.1038/nn842

    CAS  PubMed  Google Scholar 

  • Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nolker C, Moller HJ, Wei X, Farlow M, Sommer N, Oertel WH (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 75(10):1472–1474. doi:10.1136/jnnp.2003.033399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 12(3):233–243. doi:10.1016/S1474-4422(13)70014-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):311–321. doi:10.1056/NEJMoa1312889

    Article  CAS  PubMed  Google Scholar 

  • Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383(6602):710–713

    Article  CAS  PubMed  Google Scholar 

  • Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol 14(1):11–20

    Article  CAS  PubMed  Google Scholar 

  • Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M, AN1792(QS-21)-201 Study (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64(9):1563–1572. doi:10.1212/01.WNL.0000159743.08996.99

    Article  CAS  PubMed  Google Scholar 

  • Frenkel D, Balass M, Solomon B (1998) N-terminal EFRH sequence of Alzheimer’s beta-amyloid peptide represents the epitope of its anti-aggregating antibodies. J Neuroimmunol 88(1–2):85–90

    Article  CAS  PubMed  Google Scholar 

  • Frenkel D, Maron R, Burt DS, Weiner HL (2005) Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 115(9):2423–2433. doi:10.1172/JCI23241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G (2003) Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 126(Pt 2):285–291

    Article  PubMed  Google Scholar 

  • Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373(6514):523–527

    Article  CAS  PubMed  Google Scholar 

  • Garber K (2012) Genentech’s Alzheimer’s antibody trial to study disease prevention. Nat Biotechnol 30(8):731–732. doi:10.1038/nbt0812-731

    Article  CAS  PubMed  Google Scholar 

  • Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, AN1792(QS-21)-201 Study Team (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64(9):1553–1562. doi:10.1212/01.WNL.0000159740.16984.3C

    Article  CAS  PubMed  Google Scholar 

  • Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3):885–890

    Article  CAS  PubMed  Google Scholar 

  • Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349(6311):704–706. doi:10.1038/349704a0

    Article  CAS  PubMed  Google Scholar 

  • Godyn J, Jonczyk J, Panek D, Malawska B (2016) Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep 68(1):127–138. doi:10.1016/j.pharep.2015.07.006

    Article  CAS  PubMed  Google Scholar 

  • Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293(5534):1491–1495

    Article  CAS  PubMed  Google Scholar 

  • Hara H, Monsonego A, Yuasa K, Adachi K, Xiao X, Takeda S, Takahashi K, Weiner HL, Tabira T (2004) Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer’s disease. J Alzheimers Dis 6(5):483–488

    CAS  PubMed  Google Scholar 

  • Hardy J (1997) Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 20(4):154–159

    Article  CAS  PubMed  Google Scholar 

  • Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM (2002) Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8(11):1270–1275. doi:10.1038/nm783

    Article  CAS  PubMed  Google Scholar 

  • Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 38(4):547–554

    Article  CAS  PubMed  Google Scholar 

  • Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O’Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4(1):97–100

    Article  CAS  PubMed  Google Scholar 

  • Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284):99–102

    Article  CAS  PubMed  Google Scholar 

  • Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, Mayeux R (2001) Autoantibodies to amyloid-beta and Alzheimer’s disease. Ann Neurol 49(6):808–810

    Article  CAS  PubMed  Google Scholar 

  • Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408(6815):979–982. doi:10.1038/35050110

    Article  CAS  PubMed  Google Scholar 

  • Jindal H, Bhatt B, Sk S, Singh Malik J (2014) Alzheimer disease immunotherapeutics: then and now. Hum Vaccin Immunother 10(9):2741–2743. doi:10.4161/21645515.2014.970959

    Article  PubMed  PubMed Central  Google Scholar 

  • Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Chan M, Ghassemi A (2015) IVIG treatment of mild cognitive impairment due to Alzheimer’s disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2015-311486

    PubMed  Google Scholar 

  • Kim HD, Kong FK, Cao Y, Lewis TL, Kim H, Tang DC, Fukuchi K (2004) Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Neurosci Lett 370(2–3):218–223. doi:10.1016/j.neulet.2004.08.059

    Article  CAS  PubMed  Google Scholar 

  • Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11(5):556–561. doi:10.1038/nm1234

    Article  CAS  PubMed  Google Scholar 

  • Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M (2014) First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alzheimers Res Ther 6(4):44. doi:10.1186/alzrt278

    Article  PubMed  PubMed Central  Google Scholar 

  • Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH (2002) Reversible memory loss in a mouse transgenic model of Alzheimer’s disease. J Neurosci 22(15):6331–6335

    CAS  PubMed  Google Scholar 

  • Lavie V, Becker M, Cohen-Kupiec R, Yacoby I, Koppel R, Wedenig M, Hutter-Paier B, Solomon B (2004) EFRH-phage immunization of Alzheimer’s disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci 24(1):105–113. doi:10.1385/JMN:24:1:105

    Article  CAS  PubMed  Google Scholar 

  • Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD (2002) Intranasal immunotherapy for the treatment of Alzheimer’s disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 23(6):991–1000

    Article  CAS  PubMed  Google Scholar 

  • Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293(5534):1487–1491. doi:10.1126/science.1058189

    Article  CAS  PubMed  Google Scholar 

  • Li Q, Cao C, Chackerian B, Schiller J, Gordon M, Ugen KE, Morgan D (2004) Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci 5:21. doi:10.1186/1471-2202-5-21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Loeffler DA (2013) Intravenous immunoglobulin and Alzheimer’s disease: what now? J Neuroinflammation 10:70. doi:10.1186/1742-2094-10-70

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64(1):129–131. doi:10.1212/01.WNL.0000148590.39911.DF

    Article  CAS  PubMed  Google Scholar 

  • McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8(11):1263–1269. doi:10.1038/nm790

    Article  CAS  PubMed  Google Scholar 

  • Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ (2013) Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 169(10):737–743. doi:10.1016/j.neurol.2013.07.017

    Article  CAS  Google Scholar 

  • Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL (2001) Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer’s disease. Proc Natl Acad Sci U S A 98(18):10273–10278. doi:10.1073/pnas.191118298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408(6815):982–985

    Article  CAS  PubMed  Google Scholar 

  • Nath A, Hall E, Tuzova M, Dobbs M, Jons M, Anderson C, Woodward J, Guo Z, Fu W, Kryscio R, Wekstein D, Smith C, Markesbery WR, Mattson MP (2003) Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer’s disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med 3(1):29–39

    Article  CAS  PubMed  Google Scholar 

  • Nicolau C, Greferath R, Balaban TS, Lazarte JE, Hopkins RJ (2002) A liposome-based therapeutic vaccine against beta-amyloid plaques on the pancreas of transgenic NORBA mice. Proc Natl Acad Sci U S A 99(4):2332–2337. doi:10.1073/pnas.022627199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9(4):448–452. doi:10.1038/nm840

    Article  CAS  PubMed  Google Scholar 

  • Nitsch RM (2004) Immunotherapy of Alzheimer disease. Alzheimer Dis Assoc Disord 18(4):185–189

    CAS  PubMed  Google Scholar 

  • Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39(3):409–421

    Article  CAS  PubMed  Google Scholar 

  • Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43(3):321–332. doi:10.1016/j.neuron.2004.07.003

    Article  CAS  PubMed  Google Scholar 

  • Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1):46–54

    Article  CAS  PubMed  Google Scholar 

  • Panza F, Solfrizzi V, Imbimbo BP, Giannini M, Santamato A, Seripa D, Logroscino G (2014a) Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease. Expert Rev Neurother 14(9):973–986. doi:10.1586/14737175.2014.945522

    Article  CAS  PubMed  Google Scholar 

  • Panza F, Solfrizzi V, Imbimbo BP, Logroscino G (2014b) Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return? Expert Opin Biol Ther 14(10):1465–1476. doi:10.1517/14712598.2014.935332

    Article  CAS  PubMed  Google Scholar 

  • Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G (2014c) Amyloid-based immunotherapy for Alzheimer’s disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol 10(3):405–419. doi:10.1586/1744666X.2014.883921

    Article  CAS  PubMed  Google Scholar 

  • Pedersen JT, Sigurdsson EM (2015) Tau immunotherapy for Alzheimer’s disease. Trends Mol Med 21(6):394–402. doi:10.1016/j.molmed.2015.03.003

    Article  CAS  PubMed  Google Scholar 

  • Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 342(8873):697–699

    Article  CAS  PubMed  Google Scholar 

  • Ryan JM, Grundman M (2009) Anti-amyloid-beta immunotherapy in Alzheimer’s disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis 17(2):243. doi:10.3233/JAD-2009-1118

    PubMed  Google Scholar 

  • Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Bapineuzumab 301 and 302 Clinical Trial Investigators (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):322–333. doi:10.1056/NEJMoa1304839

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schenk D (2002) Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat Rev Neurosci 3(10):824–828. doi:10.1038/nrn938

    Article  CAS  PubMed  Google Scholar 

  • Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173–177. doi:10.1038/22124

    Article  CAS  PubMed  Google Scholar 

  • Schneeberger A, Mandler M, Mattner F, Schmidt W (2010) AFFITOME(R) technology in neurodegenerative diseases: the doubling advantage. Hum Vaccin 6(11):948–952

    Article  CAS  PubMed  Google Scholar 

  • Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Perkicak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375(6534):754–760. doi:10.1038/375754a0

    Article  CAS  PubMed  Google Scholar 

  • Sigurdsson EM, Wisniewski T, Frangione B (2002) A safer vaccine for Alzheimer’s disease? Neurobiol Aging 23(6):1001–1008

    Article  CAS  PubMed  Google Scholar 

  • Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer’s disease mouse model immunized with amyloid-beta derivatives. J Neurosci 24(28):6277–6282. doi:10.1523/JNEUROSCI.1344-04.2004

    Article  CAS  PubMed  Google Scholar 

  • Solomon B, Koppel R, Hanan E, Katzav T (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A 93(1):452–455

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Solomon B, Koppel R, Frankel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 94(8):4109–4112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M, AN1792 (QS-21)-251 Study Team (2009) Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 6(2):144–151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880):535–539. doi:10.1038/416535a

    Article  CAS  PubMed  Google Scholar 

  • Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, McLean CA, Villemagne VL, Parker MW, Barnham KJ, Miles LA (2014) Do current therapeutic anti-Abeta antibodies for Alzheimer’s disease engage the target? Acta Neuropathol 127(6):803–810. doi:10.1007/s00401-014-1290-2

    Article  CAS  PubMed  Google Scholar 

  • Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ (2001) Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J Immunol 166(12):7496–7503

    Article  CAS  PubMed  Google Scholar 

  • Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease. Ann Neurol 48(4):567–579

    Article  CAS  PubMed  Google Scholar 

  • Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 37(7):943–948

    Article  CAS  PubMed  Google Scholar 

  • Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, Jennings GT, Luond R, Ortmann R, Reichwald J, Zurini M, Mir A, Bachmann MF, Staufenbiel M (2011) The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31(25):9323–9331. doi:10.1523/JNEUROSCI.0293-11.2011

    Article  CAS  PubMed  Google Scholar 

  • Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23(9):3745–3751

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

I would like to thank Drs. Dave Morgan and Marcia N. Gordon at University of South Florida for contributing the original version of the chapter.

Author information

Authors and Affiliations

  1. Departments of Pharmacology and Experimental Therapeutics and Neurology, Boston University School of Medicine, 72 E Concord St, L-606B, Boston, MA, 02118, USA

    Tsuneya Ikezu

Authors
  1. Tsuneya Ikezu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsuneya Ikezu .

Editor information

Editors and Affiliations

  1. Departments of Pharmacology and Experimental Therapeutics and Neurology, Boston University School of Medicine, Boston, Massachusetts, USA

    Tsuneya Ikezu

  2. Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center Nebraska Medical Center, Omaha, Nebraska, USA

    Howard E. Gendelman

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ikezu, T. (2017). Immunotherapy for Alzheimer’s Disease. In: Ikezu, T., Gendelman, H. (eds) Neuroimmune Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-44022-4_45

Download citation

Publish with us

Policies and ethics

Search

Navigation